Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 48

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 48
---
 board of directors believes better positions DiamiR for long -termsuccess. Interests of Aptorum Directors and Officers in the Merger In considering the recommendation of the Aptorum Board with respect to issuing shares of Aptorum Delaware common stock in the Merger and the other matters to be acted upon by the Aptorum shareholders at the Special Meeting, the Aptorum shareholders should be aware that Aptorum directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Aptorum shareholders generally. These interests may present Aptorum directors and executive officers with actual or potential conflicts of interest. For example, Aptorum’s directors and officers will be eligible for continued indemnification and continued coverage under directors’ and officers’ liability insurance after the Closing and pursuant to the terms of the Merger Agreement. 7 As of September30, 2025, Aptorum’s directors and executive officers owned, in the aggregate, 10.28% of the outstanding shares of Aptorum’s Class A ordinary shares. The Aptorum Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Aptorum shareholders approve the proposals to be presented to the Aptorum shareholders for consideration at the Special Meeting as contemplated by this proxy statement/prospectus. Interests of DiamiR Directors and Officers in the Merger In considering the recommendation of the DiamiR Board with respect to approving the Merger, stockholders should be aware that DiamiR directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of DiamiR stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. From June 2020 through April 2023, Kira Sheinerman, one of the founders and the Executive Director of DiamiR, served as senior strategic consultant to Aptorum, which role included reviewing therapeutic and diagnostic opportunities, and making industry and academia introductions for Aptorum. Dr. Sheinerman currently holds 2,772shares of Aptorum’s Class A ordinary shares. Dr. Sheinerman is also a managing director of Wainwright and shall be appointed to the Combined Company’s board of directors. Dr. Mireskandari who currently serve as DiamiR’s Chief Executive Officer and one of its directors, shall serve as the Combined Company’s